FDA Finally Allows AstraZeneca To Restart US COVID-19 Vaccine
Trials Tyler
Durden Fri, 10/23/2020 – 14:43
More than a month after US authorities halted trials for the
AstraZeneca-Oxford COVID-19 vaccine, the FDA has reportedly signed
off on allowing AstraZeneca to move forward, despite the recent
death of a patient in one of its Brazilian trials (though it
appears now that the subject received a placebo, not the vaccine
candidate itself).
Per
WSJ, the FDA has finally finished its investigation into an
incident in September where two subjects in a UK trial of the
vaccine appeared to develop symptoms of a rare neurological
disorder. Any connection to the vaccine has been conclusively ruled
out, as the regulator corroborated findings from British
regulators. The FDA has spent weeks investigating whether the
symptoms of transverse myelitis, which has been linked in the past
to adenirus-vector vaccines similar to the COVID-19 vaccine being
tested by AZN, had any connection to the trial.
Trials were halted in the US for weeks, but have continued
pretty much everywhere else, including the UK and Brazil.
Shares of the drugmaker rallied on the news.
